Literature DB >> 32656538

Profiling APOL1 Nephropathy Risk Variants in Genome-Edited Kidney Organoids with Single-Cell Transcriptomics.

Esther Liu1, Behram Radmanesh1, Byungha H Chung2, Benjamin S Freedman2,3, Jennie Lin1,4, Michael D Donnan1, Dan Yi1, Amal Dadi1, Kelly D Smith3, Jonathan Himmelfarb2, Mingyao Li5.   

Abstract

BACKGROUND: DNA variants in APOL1 associate with kidney disease, but the pathophysiologic mechanisms remain incompletely understood. Model organisms lack the APOL1 gene, limiting the degree to which disease states can be recapitulated. Here we present single-cell RNA sequencing (scRNA-seq) of genome-edited human kidney organoids as a platform for profiling effects of APOL1 risk variants in diverse nephron cell types.
METHODS: We performed footprint-free CRISPR-Cas9 genome editing of human induced pluripotent stem cells (iPSCs) to knock in APOL1 high-risk G1 variants at the native genomic locus. iPSCs were differentiated into kidney organoids, treated with vehicle, IFN-γ, or the combination of IFN-γ and tunicamycin, and analyzed with scRNA-seq to profile cell-specific changes in differential gene expression patterns, compared with isogenic G0 controls.
RESULTS: Both G0 and G1 iPSCs differentiated into kidney organoids containing nephron-like structures with glomerular epithelial cells, proximal tubules, distal tubules, and endothelial cells. Organoids expressed detectable APOL1 only after exposure to IFN-γ. scRNA-seq revealed cell type-specific differences in G1 organoid response to APOL1 induction. Additional stress of tunicamycin exposure led to increased glomerular epithelial cell dedifferentiation in G1 organoids.
CONCLUSIONS: Single-cell transcriptomic profiling of human genome-edited kidney organoids expressing APOL1 risk variants provides a novel platform for studying the pathophysiology of APOL1-mediated kidney disease.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32656538      PMCID: PMC7351353          DOI: 10.34067/kid.0000422019

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  46 in total

1.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

2.  Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress.

Authors:  Tracie A Seimon; Marissa J Nadolski; Xianghai Liao; Jorge Magallon; Matthew Nguyen; Nicole T Feric; Marlys L Koschinsky; Richard Harkewicz; Joseph L Witztum; Sotirios Tsimikas; Douglas Golenbock; Kathryn J Moore; Ira Tabas
Journal:  Cell Metab       Date:  2010-11-03       Impact factor: 27.287

3.  Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe-/- and Ldlr-/- mice lacking CHOP.

Authors:  Edward Thorp; Gang Li; Tracie A Seimon; George Kuriakose; David Ron; Ira Tabas
Journal:  Cell Metab       Date:  2009-05       Impact factor: 27.287

4.  Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion.

Authors:  Daniel Granado; Daria Müller; Vanessa Krausel; Etty Kruzel-Davila; Christian Schuberth; Melanie Eschborn; Roland Wedlich-Söldner; Karl Skorecki; Hermann Pavenstädt; Ulf Michgehl; Thomas Weide
Journal:  J Am Soc Nephrol       Date:  2017-07-10       Impact factor: 10.121

5.  Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs.

Authors:  Amy L Firth; Tushar Menon; Gregory S Parker; Susan J Qualls; Benjamin M Lewis; Eugene Ke; Carl T Dargitz; Rebecca Wright; Ajai Khanna; Fred H Gage; Inder M Verma
Journal:  Cell Rep       Date:  2015-08-20       Impact factor: 9.423

6.  Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci.

Authors:  Evanthia E Pashos; YoSon Park; Xiao Wang; Avanthi Raghavan; Wenli Yang; Deepti Abbey; Derek T Peters; Juan Arbelaez; Mayda Hernandez; Nicolas Kuperwasser; Wenjun Li; Zhaorui Lian; Ying Liu; Wenjian Lv; Stacey L Lytle-Gabbin; Dawn H Marchadier; Peter Rogov; Jianting Shi; Katherine J Slovik; Ioannis M Stylianou; Li Wang; Ruilan Yan; Xiaolan Zhang; Sekar Kathiresan; Stephen A Duncan; Tarjei S Mikkelsen; Edward E Morrisey; Daniel J Rader; Christopher D Brown; Kiran Musunuru
Journal:  Cell Stem Cell       Date:  2017-04-06       Impact factor: 24.633

7.  Confirmation of Causal rs9349379- PHACTR1 Expression Quantitative Trait Locus in Human-Induced Pluripotent Stem Cell Endothelial Cells.

Authors:  Xiao Wang; Kiran Musunuru
Journal:  Circ Genom Precis Med       Date:  2018-10

8.  Gene-Edited Human Kidney Organoids Reveal Mechanisms of Disease in Podocyte Development.

Authors:  Yong Kyun Kim; Ido Refaeli; Craig R Brooks; Peifeng Jing; Ramila E Gulieva; Michael R Hughes; Nelly M Cruz; Yannan Liu; Angela J Churchill; Yuliang Wang; Hongxia Fu; Jeffrey W Pippin; Lih Y Lin; Stuart J Shankland; A Wayne Vogl; Kelly M McNagny; Benjamin S Freedman
Journal:  Stem Cells       Date:  2017-09-29       Impact factor: 6.277

9.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

10.  Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids.

Authors:  Benjamin S Freedman; Craig R Brooks; Albert Q Lam; Hongxia Fu; Ryuji Morizane; Vishesh Agrawal; Abdelaziz F Saad; Michelle K Li; Michael R Hughes; Ryan Vander Werff; Derek T Peters; Junjie Lu; Anna Baccei; Andrew M Siedlecki; M Todd Valerius; Kiran Musunuru; Kelly M McNagny; Theodore I Steinman; Jing Zhou; Paul H Lerou; Joseph V Bonventre
Journal:  Nat Commun       Date:  2015-10-23       Impact factor: 14.919

View more
  4 in total

Review 1.  Apolipoprotein L1 and mechanisms of kidney disease susceptibility.

Authors:  Leslie A Bruggeman; John R Sedor; John F O'Toole
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-05-01       Impact factor: 2.894

2.  JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.

Authors:  Sarah E Nystrom; Guojie Li; Somenath Datta; Karen L Soldano; Daniel Silas; Astrid Weins; Gentzon Hall; David B Thomas; Opeyemi A Olabisi
Journal:  JCI Insight       Date:  2022-06-08

3.  Cross-validation of SARS-CoV-2 responses in kidney organoids and clinical populations.

Authors:  Louisa Helms; Silvia Marchiano; Ian B Stanaway; Tien-Ying Hsiang; Benjamin A Juliar; Shally Saini; Yan Ting Zhao; Akshita Khanna; Rajasree Menon; Fadhl Alakwaa; Carmen Mikacenic; Eric D Morrell; Mark M Wurfel; Matthias Kretzler; Jennifer L Harder; Charles E Murry; Jonathan Himmelfarb; Hannele Ruohola-Baker; Pavan K Bhatraju; Michael Gale; Benjamin S Freedman
Journal:  JCI Insight       Date:  2021-12-22

4.  Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.

Authors:  Gizelle M McCarthy; Angelo Blasio; Olivia G Donovan; Lena B Schaller; Althea Bock-Hughes; Jose M Magraner; Jung Hee Suh; Calum F Tattersfield; Isaac E Stillman; Shrijal S Shah; Zsuzsanna K Zsengeller; Balajikarthick Subramanian; David J Friedman; Martin R Pollak
Journal:  Dis Model Mech       Date:  2021-08-05       Impact factor: 5.758

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.